Dual HER2 blockade in patients with HER2-positive breast cancer after pCR

Dual HER2 blockade in patients with HER2-positive breast cancer after pCR

Role of HER2 expression and pCR in predicting early outcomes in HER2-positive breast cancerПодробнее

Role of HER2 expression and pCR in predicting early outcomes in HER2-positive breast cancer

Education Session: "Escalating and de-escalation - titrating the right regimen in early stage"Подробнее

Education Session: 'Escalating and de-escalation - titrating the right regimen in early stage'

HER2DX and pCR in HER2-positive breast cancer: a combined analysis of 4 neoadjuvant studiesПодробнее

HER2DX and pCR in HER2-positive breast cancer: a combined analysis of 4 neoadjuvant studies

Meet the expert : Webinar 3 - Updates in Management Of Her2 Positive Breast CancerПодробнее

Meet the expert : Webinar 3 - Updates in Management Of Her2 Positive Breast Cancer

Outcomes from ADAPT-HR-/HER2+ evaluating dual HER2 blockadeПодробнее

Outcomes from ADAPT-HR-/HER2+ evaluating dual HER2 blockade

Prof. Dr. Nadia Harbeck | 7th CME Speaker | BSBCS | PresentationПодробнее

Prof. Dr. Nadia Harbeck | 7th CME Speaker | BSBCS | Presentation

Adjuvant/Neoadjuvant Therapy for Breast Cancer: Updates and Molecular Predictors of BenefitПодробнее

Adjuvant/Neoadjuvant Therapy for Breast Cancer: Updates and Molecular Predictors of Benefit

Session 10: Emerging strategies in neoadjuvant treatment of patients with HER2 positive early br...Подробнее

Session 10: Emerging strategies in neoadjuvant treatment of patients with HER2 positive early br...